Conduction abnormalities induced by sera of patients with multifocal motor neuropathy and anti‐GM1 antibodies

Increased titers of anti‐GM1 antibodies have been associated with motor neuron disease and motor neuropathy with or without conduction block. To investigate the pathogenetic role of anti‐GM1 antibodies we injected into rat tibial nerves sera from patients with multifocal motor neuropathy and conduction block (MMN) or progressive spinal muscular atrophy (PMA), both presenting anti‐GM1 antibodies. Sera of patients with MMN produced reduction of amplitude and dispersion of compound muscle action potential from proximal stimulation. Morphometry revealed demyelination in 6.2% of fibers. Sera of patients with PMA did not produce clear‐cut electrophysiological or morphological changes. Differential effects of sera from patients presenting high‐titer anti‐GM1 antibodies, but with distinct clinical syndromes, might depend on differences in anti‐GM1 antibody affinity, valency, or ability to fix complement. Alternatively, circulating factors other than, or in addition to, anti‐GM1 antibodies present in sera of patients with MMN, but not of PMA patients, might be responsible for conduction abnormalities and reproduce them after passive transfer. © 1993 John Wiley & Sons, Inc.

[1]  S. Staugaitis,et al.  Experimental conduction block induced by serum from a patient with anti‐GM1 antibodies , 1992, Annals of neurology.

[2]  R. Lovelace,et al.  Multifocal motor neuropathy with conduction block , 1992, Neurology.

[3]  A. Pestronk,et al.  Immunosuppressive treatment in multifocal motor neuropathy , 1991, Annals of neurology.

[4]  B. Winslow,et al.  Polyneuropathy syndromes associated with serum antibodies to sulfatide and myelin‐associated glycoprotein , 1991, Neurology.

[5]  A. Hays,et al.  IgM deposits at nodes of ranvier in a patient with amyotrophic lateral sclerosis, anti‐GM1 antibodies, and multifocal motor conduction block , 1990, Annals of neurology.

[6]  J. England,et al.  A computer simulation of conduction block: Effects produced by actual block versus interphase cancellation , 1990, Annals of neurology.

[7]  L. Berg,et al.  The spectrum of neurologic disease associated with anti‐GM1 antibodies , 1990, Neurology.

[8]  A. Pestronk,et al.  Lower motor neuron syndromes defined by patterns of weakness, nerve conduction abnormalities, and high titers of antiglycolipid antibodies , 1990, Annals of neurology.

[9]  S. Lipton,et al.  A syndrome of asymmetric limb weakness with motor conduction block , 1990, Neurology.

[10]  H. Krieger,et al.  Is there a sex-phenotype association for esterase D (EC 3.1.1.1)? , 1990, Human heredity.

[11]  A. Pestronk,et al.  A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside , 1988, Annals of neurology.

[12]  G. Parry,et al.  Multifocal acquired demyelinating neuropathy masqurading as motor neuron disease , 1988, Muscle & nerve.

[13]  A. Hays,et al.  Peripheral neuropathy and anti-MAG antibodies. , 1988, Critical reviews in neurobiology.

[14]  A. Hays,et al.  Experimental demyelination of nerve induced by serum of patients with neuropathy and an anti‐MAG IgM M‐protein , 1987, Neurology.

[15]  D. Silberberg,et al.  Acute conduction block associated with experimental antiserum‐mediated demyelination of peripheral nerve , 1982, Annals of neurology.

[16]  S. Metral,et al.  [Electrophysiological and morphological effects of the injection of Guillain-Barré sera in the sciatic nerve of the rat (author's transl)]. , 1982, Revue neurologique.

[17]  THE EFFECTS OF EXPERIMENTAL DEMYELINATION ON CONDUCTION IN PERIPHERAL NERVE: A HISTOLOGICAL AND ELECTROPHYSIOLOGICAL STUDY. I. CLINICAL AND HISTOLOGICAL OBSERVATIONS. , 1963, Brain : a journal of neurology.